Field Medical has announced the commencement of first-in-human trials for its FieldForce pulsed field ablation (PFA) system at Na Homolce Hospital in Prague, Czech Republic.

FieldForce, which is said to be the first and only contact force PFA system, is designed for the treatment of life-threatening ventricular arrhythmias such as ventricular tachycardia (VT) and premature ventricular contractions (PVCs).

As part of the Ventricular Catheter Ablation Study (VCAS), the company will enrol up to 60 patients across five global sites.

This study is pivotal in demonstrating the safety and performance of the FieldForce ablation system, which aims to overcome the limitations of current PFA and radiofrequency ablation systems.

Field Medical CEO Steven Mickelsen said: “Our vision at Field Medical is to transform VT ablation into a widely available, one-hour outpatient procedure with improved safety outcomes.

“With the promising early data for our VCAS study, in much the same way that PFA transformed AF, the FieldForce ablation system is optimised to transform how ventricular arrhythmias are treated, offering hope to millions of patients worldwide.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Field Medical’s PFA technology offers a new solution with the first contact force PFA catheter optimised for the ventricle, potentially providing a predictable, time-efficient, and safer treatment option.

The VCAS study is a prospective safety and feasibility trial assessing the FieldForce Ablation System in patients with ventricular arrhythmias.

It is divided into two groups: VCAS-I, focusing on VT patients, and VCAS-II, targeting those with frequent PVCs.

Last year, Field Medical closed an oversubscribed seed round totalling $14m to help advance its catheter ablation platform.

Unnamed private investors led the convertible note investment, which aimed to support the company’s clinical development of the FieldBending technology.